These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Iron metabolism and iron chelation in the thalassaemia disorders. Pippard MJ Haematologica; 1990; 75 Suppl 5():66-71. PubMed ID: 2086383 [No Abstract] [Full Text] [Related]
3. Subcutaneous desferrioxamine: the effect of three years' treatment on liver, iron, serum ferritin, and comments on echocardiography. Flynn DM; Hoffbrand AV; Politis D Birth Defects Orig Artic Ser; 1982; 18(7):347-53. PubMed ID: 6819017 [No Abstract] [Full Text] [Related]
4. Desferrioxamine: its use in iron chelation in thalassemia. Sharma BK; Choudhury P; Dubey AP Indian Pediatr; 1990 Mar; 27(3):314-9. PubMed ID: 2190932 [No Abstract] [Full Text] [Related]
5. Early iron chelation therapy in thalassemia major. Russo G; Romeo MA; Musumeci S; Schilirò G; Di Gregorio F Haematologica; 1983; 68(1):69-73. PubMed ID: 6404710 [No Abstract] [Full Text] [Related]
6. Evaluation of desferrioxamine and ascorbic acid for the treatment of chronic iron overload. Nienhuis AW; Delea C; Aamodt R; Bartter F; Anderson WF Birth Defects Orig Artic Ser; 1976; 12(8):177-85. PubMed ID: 795481 [No Abstract] [Full Text] [Related]
12. Glucose tolerance and chelation therapy in patients with thalassaemia major. Capra L; Atti G; De Sanctis V; Candini G Haematologica; 1983; 68(1):63-8. PubMed ID: 6404709 [No Abstract] [Full Text] [Related]
13. The management of iron chelation therapy. Pippard MJ; Callender ST Br J Haematol; 1983 Aug; 54(4):503-7. PubMed ID: 6871105 [No Abstract] [Full Text] [Related]
14. Iron absorption in non-transfused iron loading anaemias: prediction of risk for iron loading, and response to iron chelation treatment, in beta thalassaemia intermedia and congenital sideroblastic anaemias. Pippard MJ; Weatherall DJ Haematologia (Budap); 1984; 17(1):17-24. PubMed ID: 6724353 [TBL] [Abstract][Full Text] [Related]
15. [Research on the effect of desferrioxamine B in patients with Cooley's disease]. Silvestroni E; Bianco I; Masi M Policlinico Prat; 1967 Dec; 74(50):1681-90. PubMed ID: 4240868 [No Abstract] [Full Text] [Related]
16. [Effect of two years of deferoxamine therapy on iron balance, ferritin, liver and heart in patients with thalassemia major]. Flückiger A; Imbach P; Pfenninger E; Stocker F; Töndury P; Wagner HP; Weber J; Zuppinger K Helv Paediatr Acta; 1985 Sep; 40(4):293-304. PubMed ID: 4077563 [TBL] [Abstract][Full Text] [Related]
17. Survival and desferrioxamine in thalassaemia major. Murray JA Br Med J (Clin Res Ed); 1982 May; 284(6326):1401. PubMed ID: 6803993 [No Abstract] [Full Text] [Related]
18. [Evaluation of iron overload in thalassemia]. Piga A; Davico S; Magliano M; Luzzatto L; Sandri A; Gabutti V Pediatr Med Chir; 1986; 8(1):9-13. PubMed ID: 3725619 [TBL] [Abstract][Full Text] [Related]
19. Ascorbic acid and iron levels in plasma and liver of vitamin C deficient guinea pigs after iron overload and desferrioxamine administration. Odumosu A Acta Vitaminol Enzymol; 1982; 4(4):299-302. PubMed ID: 7158590 [TBL] [Abstract][Full Text] [Related]
20. Desferrioxamine-induced iron outputs in Cooley's anemia. Results and perspectives. Cantore N; Tortarolo M; Volpe E; Gonnella F; Valente A; Buonanno G Haematologica; 1981 Apr; 66(2):196-207. PubMed ID: 6791996 [No Abstract] [Full Text] [Related] [Next] [New Search]